Bristol-Myers Squibb

Bristol-Myers Squibb, a US-headquartered Pharmaceutical Preparation Manufacturing company, reported its latest carbon emissions for 2025 as approximately 1.84 billion kg CO2e. This includes Scope 1 emissions of around 210.25 million kg CO2e, Scope 2 emissions (market-based) of approximately 64.26 million kg CO2e, and Scope 3 emissions totalling about 1.57 billion kg CO2e. For 2024, the company's total emissions were approximately 1.95 billion kg CO2e. In 2023, total emissions were about 2.27 billion kg CO2e, comprising roughly 213.51 million kg CO2e for Scope 1, approximately 112.59 million kg CO2e for market-based Scope 2, and around 1.94 billion kg CO2e for Scope 3.

Bristol-Myers Squibb has set ambitious climate commitments, with Science Based Targets initiative (SBTi) validated goals. The company aims for net-zero greenhouse gas emissions across its entire value chain by 2050. Near-term targets include a 54.6% absolute reduction in Scope 1 and 2 GHG emissions by 2033 from a 2022 base year. Additionally, Bristol-Myers Squibb commits to reducing absolute Scope 3 GHG emissions from fuel and energy-related activities by 54.6% within the same timeframe. The company also targets that 75% of its suppliers, by emissions covering purchased goods and services, capital goods, and upstream transportation and distribution, will have science-based targets by 2028. Long-term, Bristol-Myers Squibb plans a 90% absolute reduction in Scope 1 and 2 GHG emissions by 2050 from a 2022 base year, alongside a 90% absolute reduction in Scope 3 GHG emissions within the same timeframe.